Nasdaq
$10.08▼ 0.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $350.1MShares out 34.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
33- 6d agoPre-market26.10.19 21:13SCHEDULE 13G/AOwnership#●●●#●●●
FENNEC PHARMACEUTICALS INC.
A Schedule 13G/A filing for FENNEC PHARMACEUTICALS INC. was submitted on October 19, 2026. Orin Hirschman filed the report to disclose changes in beneficial ownership regarding the company.…more
$10.08-0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 05:054Ownership
FENNEC PHARMACEUTICALS INC.
Insider Pierre Sargis Sayad of FENNEC PHARMACEUTICALS INC. reported a change in beneficial ownership of securities effective October 12, 2026. This filing is a Form 4 statement disclosing the insider's equity transaction.…more
$10.08-0.30%vs prev closeView filingShare - 10.13After-hours26.10.14 05:054Ownership
FENNEC PHARMACEUTICALS INC.
Insider Jeffrey S. Hackman of FENNEC PHARMACEUTICALS INC. reported a change in beneficial ownership of securities effective October 12, 2026. This filing serves as an official notification to the SEC regarding the insider's equity transaction.…more
$10.08-0.30%vs prev closeView filingShare
32 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.17Pre-market26.09.17 20:30#●●●#●●●#●●●
Fennec Pharmaceuticals Reports Positive Phase 2 Results for Pedmark® in Japan…more
Fennec Pharmaceuticals announced that the Phase 2 STS-J01 clinical trial in Japan demonstrated that Pedmark® significantly reduced cisplatin-induced hearing loss in pediatric and young adult patients. These results support the company's ongoing efforts to register the drug in Japan and explore potential regional licensing partnerships.…more
$10.08-0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.11Pre-market26.08.11 20:01
●●●●●●●● ●●●●● ●●●●●●
페넥 파마슈티컬스는 주력 제품인 페드마크의 수요 증가에 힘입어 2분기 매출이 전년 동기 대비 78% 성장한 1,710만 달러를 기록했습니다. 영업이익 흑자 전환과 함께 견고한 실적을 달성하며 상업적 성장 전략이 효과를 거두고 있음을 입증했습니다.…more
$10.08-0.30%vs prev close - 8.5Pre-market26.08.05 20:01
●●●●●●●● ●●●●● ●●●●●●
페넥 파마슈티컬스가 오는 8월 11일 미국 증시 개장 전 2026년 2분기 재무 실적을 발표합니다. 실적 발표와 함께 경영진이 컨퍼런스 콜을 통해 사업 성과를 논의할 예정입니다.…more
$10.08-0.30%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report